BioStock: Ultimovacs CEO - "Data could put us at the forefront of cancer vaccine field"

Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothelioma. The company’s CEO Carlos de Sousa talked to BioStock about the results and what they mean for the oncology field. 

Watch the interview with Carlos de Sousa at biostock.se

https://www.biostock.se/en/2023/11/data-could-put-ultimovacs-at-the-forefront-of-cancer-vaccine-field/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/